#research #structuralbiology #antifungalresearch
Structural characterization and inhibition of carbonic anhydrase from Candida parapsilosis
(Dostál et al., Vrábel, Heidingsfeld, Pichová) – Journal of Structural Biology: X: doi.org/10.1016/j.yj...
@iocbprague.bsky.social @czechacademy.bsky.social
Structural characterization and inhibition of carbonic anhydrase from Candida parapsilosis
(Dostál et al., Vrábel, Heidingsfeld, Pichová) – Journal of Structural Biology: X: doi.org/10.1016/j.yj...
@iocbprague.bsky.social @czechacademy.bsky.social
December 19, 2025 at 11:58 AM
#research #structuralbiology #antifungalresearch
Structural characterization and inhibition of carbonic anhydrase from Candida parapsilosis
(Dostál et al., Vrábel, Heidingsfeld, Pichová) – Journal of Structural Biology: X: doi.org/10.1016/j.yj...
@iocbprague.bsky.social @czechacademy.bsky.social
Structural characterization and inhibition of carbonic anhydrase from Candida parapsilosis
(Dostál et al., Vrábel, Heidingsfeld, Pichová) – Journal of Structural Biology: X: doi.org/10.1016/j.yj...
@iocbprague.bsky.social @czechacademy.bsky.social
🚨 New study alert!
Breakthrough invasive mould infections can still occur under posaconazole prophylaxis in patients with haematologic malignancies—linked to high mortality despite adequate drug levels. Read the full case–control study 👉 doi.org/10.1111/myc....
#Haematology #AntifungalResearch
Breakthrough invasive mould infections can still occur under posaconazole prophylaxis in patients with haematologic malignancies—linked to high mortality despite adequate drug levels. Read the full case–control study 👉 doi.org/10.1111/myc....
#Haematology #AntifungalResearch
Breakthrough Invasive Mould Infections Under Posaconazole Prophylaxis in Patients With Haematologic Malignancies: A Case–Control Study
Background Posaconazole (POS) prophylaxis is recommended for the prevention of invasive mould infections among patients with haematologic cancer and prolonged neutropenia or following allogeneic hae...
doi.org
October 16, 2025 at 10:28 AM
🚨 New study alert!
Breakthrough invasive mould infections can still occur under posaconazole prophylaxis in patients with haematologic malignancies—linked to high mortality despite adequate drug levels. Read the full case–control study 👉 doi.org/10.1111/myc....
#Haematology #AntifungalResearch
Breakthrough invasive mould infections can still occur under posaconazole prophylaxis in patients with haematologic malignancies—linked to high mortality despite adequate drug levels. Read the full case–control study 👉 doi.org/10.1111/myc....
#Haematology #AntifungalResearch
💡 New in NARMME: TRL1 enzyme from Candida glabrata changes shape to control RNA repair, vital for fungal survival. Its absence in humans makes it a promising antifungal drug target.
📖 Read more: doi.org/10.1093/narm...
#TRL1 #RNARepair #AntifungalResearch #DrugDiscovery #NARMME #OpenAccess
📖 Read more: doi.org/10.1093/narm...
#TRL1 #RNARepair #AntifungalResearch #DrugDiscovery #NARMME #OpenAccess
September 18, 2025 at 4:56 PM
💡 New in NARMME: TRL1 enzyme from Candida glabrata changes shape to control RNA repair, vital for fungal survival. Its absence in humans makes it a promising antifungal drug target.
📖 Read more: doi.org/10.1093/narm...
#TRL1 #RNARepair #AntifungalResearch #DrugDiscovery #NARMME #OpenAccess
📖 Read more: doi.org/10.1093/narm...
#TRL1 #RNARepair #AntifungalResearch #DrugDiscovery #NARMME #OpenAccess
Antifungal Properties of Polycephalomyces nipponicus (Ascomycetes) against Candida albicans: Potential for Novel Therapeutic Development
dl.begellhouse.com/journals/708...
#AntifungalResearch #DrugDiscovery #CandidaAlbicans
dl.begellhouse.com/journals/708...
#AntifungalResearch #DrugDiscovery #CandidaAlbicans
July 29, 2025 at 3:37 PM
Antifungal Properties of Polycephalomyces nipponicus (Ascomycetes) against Candida albicans: Potential for Novel Therapeutic Development
dl.begellhouse.com/journals/708...
#AntifungalResearch #DrugDiscovery #CandidaAlbicans
dl.begellhouse.com/journals/708...
#AntifungalResearch #DrugDiscovery #CandidaAlbicans
🚀 Excited to share our latest research on antifungal drug discovery! 🍄💊
We use humanized Candida models and NanoBiT assays to identify selective inhibitors of the Bdf1 bromodomain, a promising antifungal target.
doi.org/10.1002/advs...
#AntifungalResearch #DrugDiscovery
A 🧵 1/6 👇
We use humanized Candida models and NanoBiT assays to identify selective inhibitors of the Bdf1 bromodomain, a promising antifungal target.
doi.org/10.1002/advs...
#AntifungalResearch #DrugDiscovery
A 🧵 1/6 👇
Humanized Candida and NanoBiT Assays Expedite Discovery of Bdf1 Bromodomain Inhibitors With Antifungal Potential
The fungal BET protein Bdf1 is a potential antifungal target in pathogenic Candida species requiring the inhibition of both its bromodomains. Humanized Candida strains and NanoBiT complementation ass...
doi.org
February 3, 2025 at 10:13 AM
🚀 Excited to share our latest research on antifungal drug discovery! 🍄💊
We use humanized Candida models and NanoBiT assays to identify selective inhibitors of the Bdf1 bromodomain, a promising antifungal target.
doi.org/10.1002/advs...
#AntifungalResearch #DrugDiscovery
A 🧵 1/6 👇
We use humanized Candida models and NanoBiT assays to identify selective inhibitors of the Bdf1 bromodomain, a promising antifungal target.
doi.org/10.1002/advs...
#AntifungalResearch #DrugDiscovery
A 🧵 1/6 👇
🚀 Just published, our review of direct antifungal drug delivery approaches for invasive fungal infections.
Evidence is still limited, but trials are underway. Extra options, fewer side effects, better patient outcomes 🚀
#AntifungalResearch #HealthcareInnovation
pubmed.ncbi.nlm.nih.gov/39317940/
Evidence is still limited, but trials are underway. Extra options, fewer side effects, better patient outcomes 🚀
#AntifungalResearch #HealthcareInnovation
pubmed.ncbi.nlm.nih.gov/39317940/
December 11, 2024 at 11:22 PM
🚀 Just published, our review of direct antifungal drug delivery approaches for invasive fungal infections.
Evidence is still limited, but trials are underway. Extra options, fewer side effects, better patient outcomes 🚀
#AntifungalResearch #HealthcareInnovation
pubmed.ncbi.nlm.nih.gov/39317940/
Evidence is still limited, but trials are underway. Extra options, fewer side effects, better patient outcomes 🚀
#AntifungalResearch #HealthcareInnovation
pubmed.ncbi.nlm.nih.gov/39317940/